CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1

Dec 2, 2025Hypertension (Dallas, Tex. : 1979)

CagriSema lowers blood pressure in overweight and obese adults

AI simplified

GLP-1 Therapies on OpenScience ↗PubMed ↗DOI ↗OA ↗

Abstract

In a trial with 3,417 participants, CagriSema 2.4 mg/2.4 mg resulted in a 10.9 mm Hg reduction in systolic blood pressure compared to a 2.8 mm Hg reduction with placebo.

CagriSema is associated with a higher proportion of participants reaching blood pressure targets at week 68 compared to placebo (63.0% vs. 32.0%).
Among participants with resistant hypertension at baseline, a greater percentage reached blood pressure targets with CagriSema than with placebo (42.0% vs. 29.3%).
Participants using antihypertensive medication showed a significant reduction in treatment frequency, with 39.6% in the CagriSema group decreasing or stopping their medication compared to 18.8% in the placebo group.
The findings suggest potential benefits of CagriSema in managing blood pressure in adults with overweight or obesity.

AI simplified

BACKGROUND: Fixed-dose combination of semaglutide/cagrilintide (CagriSema 2.4 mg/2.4 mg) has demonstrated significant and clinically relevant body weight reductions in adults with overweight or obesity compared with placebo.

METHODS: The phase 3a, 68-week REDEFINE 1 trial randomized adults without diabetes with body mass index ≥30 kg/m, or ≥27 kg/mwith ≥1 obesity-related complication, to once-weekly CagriSema 2.4 mg/2.4 mg, semaglutide 2.4 mg, cagrilintide 2.4 mg, or placebo, plus lifestyle intervention. Secondary and post hoc analyses evaluated the antihypertensive effect from REDEFINE 1, focusing on CagriSema and placebo groups, by subgroup/category, including baseline body mass index, the presence of hypertension or resistant hypertension at baseline, and concomitant changes in the use of antihypertensive medications. 2 2

RESULTS: Overall, 3417 participants underwent randomization; CagriSema: n=2108, semaglutide: n=302, cagrilintide: n=302, and placebo: n=705. Changes from baseline to week 68 in blood pressure (BP) were greater with CagriSema versus placebo (systolic BP: -10.9 versus -2.8 mm Hg; diastolic BP: -5.4 versus -1.7 mm Hg, respectively). The proportion of participants reaching BP targets at week 68 was 63.0% and 32.0% for CagriSema and placebo, respectively. The proportion of participants with resistant hypertension at baseline (n=167) that reached BP targets at week 68 was 42.0% and 29.3% for CagriSema and placebo, respectively (odds ratio, 1.7 [95% CI, 0.7-4.4]). Among participants who used antihypertensive medication during the study, 39.6% in the CagriSema group decreased or stopped treatment from week 0 to week 68 versus 18.8% with placebo.

CONCLUSIONS: CagriSema presents clinically relevant reductions in BP across a wide range of participant subgroups, including those with resistant hypertension.

REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT05567796.

Full Text

Full text is available at the source.

View full text ↗

CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief